-
Scholar Rock Holding Corp NASDAQ:SRRK Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock's approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
Location: 620 Memorial Dr Fl 2, Massachusetts, 02139-4815, United States | Website: www.scholarrock.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.313B
Cash
190.5M
Avg Qtr Burn
-42.15M
Short % of Float
25.04%
Insider Ownership
1.07%
Institutional Own.
-
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Apitegromab (SRK-015) Details Genetic disorder, Spinal muscular atrophy | BLA Submission | |
Phase 2 Data readout | ||
SRK-181 (TGFβ1) Details Solid tumor/s, Cancer | Phase 1 Update | |
SRK-439 Details Obesity | IND Submission |